SER | tickerfilter.com

Fundamental analysis

32%

Profitability 33%

Dept financing 33%

Liquidity 35%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.65%

1 Month

8.37%

3 Months

12.12%

6 Months

-25.79%

1 Year

-53.50%

2 Year

-78.02%

Key data

Stock price

$5.18

P/E Ratio

0.00

DAY RANGE

$5.10 - $5.24

EPS

-$1.13

52 WEEK RANGE

$3.81 - $14.57

52 WEEK CHANGE

-$53.50

MARKET CAP

36.869 M

YIELD

N/A

SHARES OUTSTANDING

8.881 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-24-2025

BETA

-1.90

PUBLIC FLOAT

AVERAGE 10 VOLUME

$14,060

AVERAGE 30 VOLUME

$12,140

Company detail

CEO: Steven A. Ledger
Region: US
Website: serinatherapeutics.com
Employees: 0
IPO year: 2018

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

SER - Serina Therapeutics, Inc.